Last Price
2.79
Today's Change
+0.13 (4.88%)
Day's Change
2.69 - 2.81
Trading Volume
235,905
Market Cap
369 Million
Shares Outstanding
132 Million
Avg Volume
1,270,319
Avg Price (50 Days)
2.63
Avg Price (200 Days)
2.93
PE Ratio
69.75
EPS
0.04
Earnings Announcement
07-Aug-2024
Previous Close
2.66
Open
2.69
Day's Range
2.69 - 2.81
Year Range
1.96 - 4.705
Trading Volume
235,905
1 Day Change
4.89%
5 Day Change
1.82%
1 Month Change
11.16%
3 Month Change
-0.36%
6 Month Change
-25.20%
Ytd Change
-31.62%
1 Year Change
-11.99%
3 Year Change
-83.48%
5 Year Change
-64.73%
10 Year Change
-71.38%
Max Change
-71.38%
No result.
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.